Strumento inattivo

Altre lingue IceCure Medical Ltd TEL AVIV STOCK EXCHANGE

Azioni

ICCM

IL0011224156

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

European Study Provides More Evidence Supporting IceCure's ProSense is Safe and Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer	10/07
European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer	09/07
IceCure Medical Ltd. Announces the Publication of an Independent Study Evaluating its Cryoablation System ProSense	09/07
U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation System with CryoProbes	01/07
U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense Cryoablation System with CryoProbes	01/07
IceCure Medical to Provide Overview and Share Recent Progress at Northland Capital Markets Virtual Growth Conference on June 25, 2024	18/06
Positive Data from IceCure's Kidney Cancer Clinical Study Presented at Interventional Radiology Conference, Minimally Invasive Approach Results in Shorter Hospitalization and Minor Impact on Renal Function	13/06
Positive Data from IceCure's Kidney Cancer Clinical Study Presented at Interventional Radiology Conference: Minimally Invasive Approach Results in Shorter Hospitalization and Minor Impact on Renal Function	12/06
FDA to Convene Advisory Panel for Review of IceCure's De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025; Aligns with Commercial Readiness Plan	04/06
FDA to Convene Advisory Panel for Review of IceCure Medical Ltd.'s De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025	04/06
IceCure Medical : Company Presentation	03/06
IceCure Medical Maintains Positive Momentum and Reports Sales Growth for Cryoablation System in First Quarter of 2024	29/05
Earnings Flash (ICCM) ICECURE MEDICAL Posts Q1 Revenue $743,000, vs. Street Est of $880,000	28/05
IceCure Medical to Report First Quarter 2024 Financial & Operational Results on May 28, 2024	21/05
IceCure Medical to Highlight Key Achievements and Provide Business Overview at A.G.P. / Alliance Global Partners' Virtual Healthcare Company Showcase	20/05
Independent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense®, Adding to Continued Positive Data Published Globally	07/05
Icecure Medical Ltd. Announces That Positive Data from an Independent Study (The "Study") Performed in Japan Was Published in an Article Titled "Percutaneous Ultrasound?Guided Cryoablation for Early?Stage Primary Breast Cancer: A Follow?Up Study in Japan," in the Journal Breast Cancer on April 27, 2024	07/05
IceCure Medical : Company Presentation	23/04
IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate, Data Submitted to FDA Requesting Marketing Authorization	16/04
IceCure Medical Seeks FDA Nod For ProSense to Treat Early-Stage Breast Cancer	15/04

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue IceCure Medical Ltd TEL AVIV STOCK EXCHANGE

Azioni

ICCM

IL0011224156

Altre lingue

Filtri